Skip to main content

Kraig Biocraft Laboratories Receives Equipment for Onsite Testing and Screening of Transgenic Technology at Prodigy Textiles

Onsite testing to enable significant production expansion

ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces it has taken delivery of key lab equipment to Prodigy Textiles, the Company’s Vietnam based subsidiary, to support onsite testing and screening of spider silk transgenic technologies.

Over the next few weeks, the Company’s US-based research team will work closely with the Prodigy team to complete equipment installation and conduct training. Once online, this equipment will allow for the complete transfer of all genetic screening and selection testing, for production operations, to Prodigy’s onsite lab.

The significance of this advancement in the Company’s production operation cannot be overstated. Previously all genetic testing was limited to Kraig Labs US R&D headquarters. COVID-related transportation and shipping restrictions over the last 24 months have meant that critical testing was delayed and, in some cases, not possible. This, in turn, forced the Company to lower its output at Prodigy to ensure production quality. With onsite process screening, Prodigy will be able to safely and effectively scale up operations and take full advantage of Prodigy’s new facilities. The goal is to run at maximum facility capacity consistently.

Implementing in-process quality testing is yet another example of the Company’s efforts to build a completely autonomous production operation at Prodigy Textiles. The Company believes that, in blending the most advanced technologies available with the rich history of silk production in Vietnam, it is building an advanced scalable system for large-scale recombinant spider silk production.

“Once online, this equipment will allow our production team to floor the gas pedal on production,” said COO Jon Rice. “Travel and shipping delays in 2020 and 2021 demonstrated that Prodigy needed to have the tools in place to stand on its own. This onsite lab is the final element of that equation. In-process testing will give our team the tools and confidence needed to run our facilities at maximum capacity in very short order.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.